Contract facts
FederalDEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $56.5M ($15.5M obligated). Current period of performance ends May 25, 2027. Place of performance: FREDERICK, MD.
DEVELOPMENT OF TARGET CHARACTERIZATION METHODS FOR NOVEL CANCER MARKERS
Recompete timing
PublicCurrent PoP ends May 25, 2027 (278 days remaining). Agencies typically plan 12–18 months ahead — at 9.1 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordLeidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N91020F00026?
75N91020F00026 (Development of TARGET characterization methods) is a Nih Nci award with an estimated value of $56.5M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N91020F00026?
Nih Nci awarded 75N91020F00026 to Leidos Biomedical Research, Inc.
Who is the incumbent on 75N91020F00026?
Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends May 25, 2027.
When does Leidos Biomedical Research, Inc’s 75N91020F00026 come up for recompete?
SCOUT tracks a period-of-performance end of May 25, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.